CN111346228B - 胃肠道疾病的免疫机制及治疗药物 - Google Patents
胃肠道疾病的免疫机制及治疗药物 Download PDFInfo
- Publication number
- CN111346228B CN111346228B CN201910988111.0A CN201910988111A CN111346228B CN 111346228 B CN111346228 B CN 111346228B CN 201910988111 A CN201910988111 A CN 201910988111A CN 111346228 B CN111346228 B CN 111346228B
- Authority
- CN
- China
- Prior art keywords
- colitis
- gastrointestinal
- kit
- disease
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/222—Platelet disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
分选细胞类型 | 分选细胞策略 | 单细胞分析策略 |
T淋巴细胞 | PI<sup>-</sup>,CD45<sup>+</sup>,CD3<sup>+</sup>, | 5’转录组测序+TCR测序 |
B淋巴细胞 | PI<sup>-</sup>,CD45<sup>+</sup>,CD3<sup>-</sup>,CD19<sup>+</sup> | 5’转录组测序+BCR测序 |
非T非B淋巴细胞 | PI<sup>-</sup>,CD45<sup>+</sup>,CD3<sup>-</sup>,CD19- | 5’转录组测序+BCR测序 |
CD45-细胞(肠粘膜) | PI<sup>-</sup>,CD45- | 5’转录组测序 |
Claims (28)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210021325.2A CN114432451B (zh) | 2018-12-21 | 2019-10-17 | 胃肠道疾病的免疫机制及治疗药物 |
EP19901170.1A EP3900727A4 (en) | 2018-12-21 | 2019-11-15 | IMMUNITY MECHANISM AND THERAPEUTIC DRUGS FOR GASTROINTESTINAL DISEASES |
JP2021536389A JP2022514959A (ja) | 2018-12-21 | 2019-11-15 | 胃腸疾患の免疫機序及び治療薬 |
PCT/CN2019/118875 WO2020125293A1 (zh) | 2018-12-21 | 2019-11-15 | 胃肠道疾病的免疫机制及治疗药物 |
US17/416,918 US20220260566A1 (en) | 2018-12-21 | 2019-11-15 | Immunity mechanism and therapeutic drug for gastrointestinal diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018115732439 | 2018-12-21 | ||
CN201811573243 | 2018-12-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210021325.2A Division CN114432451B (zh) | 2018-12-21 | 2019-10-17 | 胃肠道疾病的免疫机制及治疗药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111346228A CN111346228A (zh) | 2020-06-30 |
CN111346228B true CN111346228B (zh) | 2022-01-14 |
Family
ID=71188473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910988111.0A Active CN111346228B (zh) | 2018-12-21 | 2019-10-17 | 胃肠道疾病的免疫机制及治疗药物 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3900727A4 (zh) |
CN (1) | CN111346228B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113244395A (zh) * | 2020-02-10 | 2021-08-13 | 广州市妇女儿童医疗中心 | 纤维化疾病机制及其治疗药物 |
CN115105509A (zh) * | 2021-03-18 | 2022-09-27 | 天津医科大学 | 双嘧达莫在制备预防和/或治疗坏死性小肠结肠炎的药物中的应用 |
CN116196314B (zh) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Ri-1或其盐在制备防治胃肠道疾病的药物中的应用 |
CN116270657B (zh) * | 2023-05-18 | 2023-08-18 | 智泽童康(广州)生物科技有限公司 | 一种预防和/或治疗胃肠道疾病的药物组合物及其用途 |
CN117187343A (zh) * | 2023-09-06 | 2023-12-08 | 青岛大学 | 一种磷酸二酯酶抑制剂的高通量筛选方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382052A (zh) * | 1999-10-22 | 2002-11-27 | 贝林格尔英格海姆法玛公司 | 潘生丁或单哌潘生丁在制备用于治疗及预防血纤维蛋白依赖性微循环障碍药物中的用途 |
CN1599613A (zh) * | 2001-10-05 | 2005-03-23 | 康宾纳特克斯公司 | 用于治疗免疫炎性疾病的联合疗法 |
WO2011038298A1 (en) * | 2009-09-25 | 2011-03-31 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of dipyridamole in chronic ischemia |
CN107106541A (zh) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA911453B (en) * | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
US20090105281A1 (en) * | 2006-04-27 | 2009-04-23 | Paul Epstein | Methods of treating inflammation |
US20130123264A1 (en) * | 2011-10-17 | 2013-05-16 | Darren D. Browning | Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers |
-
2019
- 2019-10-17 CN CN201910988111.0A patent/CN111346228B/zh active Active
- 2019-11-15 EP EP19901170.1A patent/EP3900727A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1382052A (zh) * | 1999-10-22 | 2002-11-27 | 贝林格尔英格海姆法玛公司 | 潘生丁或单哌潘生丁在制备用于治疗及预防血纤维蛋白依赖性微循环障碍药物中的用途 |
CN1599613A (zh) * | 2001-10-05 | 2005-03-23 | 康宾纳特克斯公司 | 用于治疗免疫炎性疾病的联合疗法 |
WO2011038298A1 (en) * | 2009-09-25 | 2011-03-31 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of dipyridamole in chronic ischemia |
CN107106541A (zh) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
Also Published As
Publication number | Publication date |
---|---|
CN111346228A (zh) | 2020-06-30 |
EP3900727A1 (en) | 2021-10-27 |
EP3900727A4 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111346228B (zh) | 胃肠道疾病的免疫机制及治疗药物 | |
Korhonen et al. | Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation | |
Wolf et al. | Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia | |
Monteleone et al. | Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract | |
Liu et al. | A novel benzo [d] imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome | |
Papaioannou et al. | Sonic Hedgehog signaling limits atopic dermatitis via Gli2-driven immune regulation | |
JP2022521454A (ja) | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 | |
Pereira et al. | Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response | |
WO2018025923A1 (ja) | 抗htlv-1剤、htlv-1関連脊髄症(ham/tsp)治療薬 | |
CA3014383A1 (en) | Methods of treating celiac disease using smad7 inhibition | |
CN113244395A (zh) | 纤维化疾病机制及其治疗药物 | |
Chen et al. | Maternal hypercholesterolemia exacerbates atherosclerosis lesions in female offspring through potentiating macrophage polarization toward an inflammatory M1 phenotype | |
JP2017529321A (ja) | 炎症性腸疾患を診断ならびに処置するための方法および組成物 | |
De Vries et al. | Tyrosine kinase 2 signalling drives pathogenic T cells in colitis | |
CA2962757A1 (en) | Methods and compositions for modulating th-gm cell function | |
Zhang et al. | NOX1/NADPH oxidase affects the development of autism-like behaviors in a maternal immune activation model | |
KR20150064084A (ko) | 만성 염증을 동반하는 질병을 앓는 환자의 분자 표현형의 진단 방법 | |
Dulic et al. | Specific T-cell subsets can predict the efficacy of anti-TNF treatment in inflammatory bowel diseases | |
CN114432451B (zh) | 胃肠道疾病的免疫机制及治疗药物 | |
JP2018535681A (ja) | Il−34アンチセンスオリゴヌクレオチドおよびその使用方法 | |
Yasmeen et al. | Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations | |
CN114525330B (zh) | 一种用于评估非酒精性脂肪性肝炎的标记物组 | |
Crosson et al. | IL-13 promotes sensory-sympathetic neurons crosstalk in asthma | |
Li et al. | Hsa-miR-374b-5p and hsa-miR-106a-5p are associated with inflammatory bowel disease through targeting IL-10/STAT3 axis | |
US20230151434A1 (en) | Reawakening of dormant tumor cells by modified lipids derived from stress activated neutrophils |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Yuxia Inventor after: Yang Min Inventor after: Huang Bing Inventor after: Chen Zhanghua Inventor after: Zhang Li Inventor after: Bai Fan Inventor after: Gong Sitang Inventor before: Zhang Yuxia Inventor before: Yang Min Inventor before: Huang Bing Inventor before: Chen Zhanghua Inventor before: Zhang Li Inventor before: Bai Fan Inventor before: Gong Sitang |